NM6603
Phase 1Small molecule
NM6603 is one of 74 small molecule programs targeting Advanced Solid Tumors. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
73
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
286 competitors in Advanced Solid Tumors
#DrugCompanyPhaseTrials
1Tecentriq
RochePhase 2
Imfinzi
AstraZenecaPhase 2
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 2
Alimta
SShawn Eagle
Phase 2
Myrbetriq
AstellasPhase 2
Inlyta
PPrism Pharmaceuticals
Phase 2
Trifluridine/tipiracil
AbbViePhase 2
Standard Chemotherapy
RochePhase 2
BNT327
BioNTechPhase 2
IL-2
FFate Therapeutics
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NM6603. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- NNucMito Pharmaceuticals Co. Ltd.